Arcus Biosciences Announces Commencement of Public Offering of Common Stock
Arcus Biosciences has commenced an underwritten public offering of its common stock, with all shares sold by the company. Underwriters hold a 30-day option to purchase up to an additional 15% of the shares offered; offering size, price, and terms are not yet set and remain subject to market conditions. Jefferies, Leerink Partners, and TD Cowen are joint book-running managers.
Key figures
- Overallotment option
- 30-day option for up to an additional 15% of shares offered
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.